首页> 外文OA文献 >Palbociclib and Ribociclib Analogs Targeting CDK4 and CDK6 for Breast Cancer Treatment: A Molecular Modeling Study

【2h】

Palbociclib and Ribociclib Analogs Targeting CDK4 and CDK6 for Breast Cancer Treatment: A Molecular Modeling Study

机译：Palbociclib和Ribociclib类似物靶向CDK4和CDK6，用于乳腺癌治疗：分子建模研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Dhoha TRIKI; sravya Kuchibhotla; Denis Fourches;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer [J] . Janice Lu Journal of Hematology and Oncology . 2015,第1期

机译：Palbociclib：一流的CDK4 / CDK6抑制剂，用于治疗激素受体阳性的晚期乳腺癌
2. Treatment of advanced HR+/HER2— breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib [J] . Tea M. Bottcher, Soren Cold, Anders B. Jensen Acta oncologica. . 2019,第2期

机译：用新的靶向剂治疗高级HR + / HER2-乳腺癌，与内分泌治疗组合：基于可用随机试验的疗效和耐受性的审查综述，核武器司，核武器，帕尔巴克测妇和ABEMACIBLIB
3. Synthesis, state-of-the-art NMR-binding and molecular modeling study of new benzimidazole core derivatives as Pin1 inhibitors: Targeting breast cancer [J] . Nashaat Samira, Henen Morkos A., El-Messery Shahenda M., The Journal of the American Academy of Orthopaedic Surgeons . 2020,第11期

机译：新苯并咪唑核心衍生物作为Pin1抑制剂的合成，最先进的NMR结合和分子建模研究：靶向乳腺癌
4. Proteomic Profiling of Inherited Breast Cancer: Identification of Molecular Targets for Early Detection, Prognosis and Treatment, and Related Bioinformatics Tools [C] . Giovanni Cuda, Mario Cannataro, Barbara Quaresima, Neural Nets . 2003

机译：蛋白质组学的遗传性乳腺癌：早期检测，预后和治疗以及相关生物信息学工具的分子目标的确定。
5. Identification of Genomic Predictors of Response to the CDK4/6 Inhibitor Palbociclib using the UCLATORL Panel of Human Cancer Cell Lines [D] . Conklin, Dylan Francis 2013

机译：使用人类癌细胞系UCLATORL小组鉴定对CDK4 / 6抑制剂Palbociclib应答的基因组预测因子
6. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer [O] . Janice Lu 2015

机译：Palbociclib：一流的CDK4 / CDK6抑制剂用于治疗激素受体阳性的晚期乳腺癌
7. Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer [O] . 2015

机译：Palbociclib：一流的CDK4 / CDK6抑制剂，用于治疗激素受体阳性的晚期乳腺癌
8. Novel Molecular Target for Breast Cancer Prevention and Treatment [R] . Zhang, X. 2004

机译：一种新的乳腺癌预防和治疗分子靶点

Palbociclib and Ribociclib Analogs Targeting CDK4 and CDK6 for Breast Cancer Treatment: A Molecular Modeling Study

著录项

引文网络

相似文献

相关主题

期刊订阅